Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.64 |
| ▸ | PGR | P06401 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | IL6 | P05231 | 1/20 | 0.64 |
| ▸ | GLUL | P15104 | 1/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1237365 | 0.97 | NR3C1 (0.65) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL5501494 | 0.96 | NR3C1 (0.67) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| SCHEMBL13270299 | 0.94 | HIF1A (0.72) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| SCHEMBL1512721 | 0.94 | HIF1A (0.72) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| SCHEMBL2299293 | 0.94 | HIF1A (0.72) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| SCHEMBL719929 | 0.93 | HIF1A (0.70) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL1477515 | 0.92 | HIF1A (0.64) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL40948 | 0.92 | HIF1A (0.64) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL7600416 | 0.90 | HIF1A (0.66) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL7096415 | 0.89 | HIF1A (0.63) | NR3C1HIF1AHSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-3448359-B1 | LIPOSOMAL CORTICOSTEROIDS FOR TOPICAL INJECTION IN INFLAMED LESIONS OR AREAS | LAURENTIA HOLDING B V (NL) | 2023-06-07 | — | — | EP | claimed |
| US-20190151236-A1 | LIPOSOMAL CORTICOSTEROIDS FOR TOPICAL INJECTION IN INFLAMED LESIONS OR AREAS | ENCELADUS PHARMACEUTICALS B.V. (NL) | 2019-05-23 | — | — | US | claimed |
| WO-2017188818-A1 | LIPOSOMAL CORTICOSTEROIDS FOR TOPICAL INJECTION IN INFLAMED LESIONS OR AREAS | ENCELADUS PHARMACEUTICALS B.V. (NL) | 2017-11-02 | — | — | WO | claimed |
| WO-2024123983-A1 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY ADVERSE EVENTS BASED ON IMMUNE CELL POPULATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4373495-A2 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTI-ASTHMATIC AGENT | Genetic S.p.A. (IT) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024102827-A1 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240150836-A1 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-09 | — | — | US | disclosed |
| CN-117729925-A | Sodium salt of budesonide 21-phosphate as anti-inflammatory or anti-asthmatic agent | 基因股份公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3448359-B1 | LIPOSOMAL CORTICOSTEROIDS FOR TOPICAL INJECTION IN INFLAMED LESIONS OR AREAS | LAURENTIA HOLDING B V (NL) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023001890-A2 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTI-ASTHMATIC AGENT | GENETIC S.P.A. (IT) | 2023-01-26 | — | — | WO | disclosed |
| US-20040037875-A1 | Composition for treatment of inflammatory disorders | ENCELADUS PHARMACEUTICALS B.V. (NL) | 2004-02-26 | — | — | US | disclosed |
| WO-2003105805-A1 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2003-12-24 | — | — | WO | disclosed |
| EP-1371362-A1 | Composition for treatment of inflammatory disorders | Universiteit Utrecht Holding B.V. (NL) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003082251-A2 | THE EFFERVESCENT PHARMACEUTICAL DOSAGE FORM OF ESTERS AND ESTER SALTS OF 6 α METHYLPREDNISOLONE SUCCINATE, PROCEDURE FOR ITS OBTAINING AND APPLICATION | HEMOFARM KONCERN A.D. PHARMACEUTICAL AND CHEMICAL INDUSTRY (YU) | 2003-10-09 | — | — | WO | disclosed |
| EP-1347743-A2 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | Universiteit Utrecht Holding B.V. (NL) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002045688-A2 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2002-06-13 | — | — | WO | disclosed |
| US-4678609-A | Process for the preparation of corticosteroid-21-phosphoric acids and their salts and the corticosteroid-21-phosphoric acid triesters | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-07 | — | — | US | disclosed |
| EP-0181561-A1 | Process for the preparation of corticosteroid-21-phosphoric acids and their salts, and the triesters of certicusteroid-21-phosphoric acid | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-05-21 | — | — | EP | disclosed |